Short-term use of CGM in youth onset type 2 diabetes is associated with behavioral modifications.
adolescents
barriers
continuous glucose monitors
glycemic control
type 2 diabetes
youth
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
03
2023
accepted:
10
05
2023
medline:
15
6
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
epublish
Résumé
Continuous glucose monitoring (CGM) is beneficial to glycemic control in youth with type 1 diabetes (T1D) and adults with type 2 diabetes (T2D); however, studies in youth with T2D are limited. Determine if 10-day trial CGM use in youth with T2D improves glycemic control and behavioral modifications. Youth with T2D > 3 months, on insulin, with no prior CGM use were enrolled. Staff placed CGM and provided education. Participants received 5-day and 10-day follow-up phone calls to review CGM data, behavioral modifications, and adjust insulin doses as needed. We compared 5-day to 10-day TIR, and baseline to 3-6 month HbA1c via paired t-test. Participants (n=41) had median age of 16.2 y, were 61% female, 81% NH Black, median diabetes duration of 0.8 y, and baseline HbA1c of 10.3%. A majority had household income<$50,000 (81%) and parental education level of HS or less (73%). Average 5-day TIR 49% was similar to 10-day TIR 51% (p=0.62). There was no change in HbA1c after 3-6 months (10.2% v 10.3%, p=0.89). Nineteen participants completed full 10-day CGM use; of those, 84% wanted a CGM long-term. Adolescents reported behavioral changes including increased blood sugar checks, increased insulin administration and overall improved diabetes management. Although 10-day CGM use did not impact short-term or long-term glycemic control in youth with T2D, most participants reported behavioral changes and wanted to continue using CGM. Future studies with longer use of CGM may clarify the potential impact of CGM in youth with T2D.
Sections du résumé
Background
Continuous glucose monitoring (CGM) is beneficial to glycemic control in youth with type 1 diabetes (T1D) and adults with type 2 diabetes (T2D); however, studies in youth with T2D are limited.
Objective
Determine if 10-day trial CGM use in youth with T2D improves glycemic control and behavioral modifications.
Methods
Youth with T2D > 3 months, on insulin, with no prior CGM use were enrolled. Staff placed CGM and provided education. Participants received 5-day and 10-day follow-up phone calls to review CGM data, behavioral modifications, and adjust insulin doses as needed. We compared 5-day to 10-day TIR, and baseline to 3-6 month HbA1c via paired t-test.
Results
Participants (n=41) had median age of 16.2 y, were 61% female, 81% NH Black, median diabetes duration of 0.8 y, and baseline HbA1c of 10.3%. A majority had household income<$50,000 (81%) and parental education level of HS or less (73%). Average 5-day TIR 49% was similar to 10-day TIR 51% (p=0.62). There was no change in HbA1c after 3-6 months (10.2% v 10.3%, p=0.89). Nineteen participants completed full 10-day CGM use; of those, 84% wanted a CGM long-term. Adolescents reported behavioral changes including increased blood sugar checks, increased insulin administration and overall improved diabetes management.
Conclusion
Although 10-day CGM use did not impact short-term or long-term glycemic control in youth with T2D, most participants reported behavioral changes and wanted to continue using CGM. Future studies with longer use of CGM may clarify the potential impact of CGM in youth with T2D.
Identifiants
pubmed: 37313442
doi: 10.3389/fendo.2023.1182260
pmc: PMC10258317
doi:
Substances chimiques
Glycated Hemoglobin
0
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1182260Informations de copyright
Copyright © 2023 Manfredo, Lin, Gupta, Abiola, West, Busin, Tracey, Brown, Magge and Wolf.
Déclaration de conflit d'intérêts
Author RMW reports receiving research grants from Boehringer Ingelheim outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetes Care. 2022 Feb 1;45(2):285-294
pubmed: 34995346
Curr Diab Rep. 2017 Aug;17(8):60
pubmed: 28664253
JAMA. 2017 Oct 10;318(14):1358-1366
pubmed: 29049584
JAMA. 2020 Jun 16;323(23):2388-2396
pubmed: 32543683
Diabetes Care. 2018 Oct;41(10):2064-2071
pubmed: 30061317
J Pediatr. 2022 Dec;251:51-59.e2
pubmed: 35985535
Diabetes Technol Ther. 2015 Sep;17(9):657-63
pubmed: 25923812
Diabetes Care. 2020 Oct;43(10):2537-2543
pubmed: 32723843
JAMA. 2014 May 7;311(17):1778-86
pubmed: 24794371
Diabetes Care. 2016 Jun;39(6):e81-2
pubmed: 27208319
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Ann Intern Med. 2017 Sep 19;167(6):365-374
pubmed: 28828487
Acta Diabetol. 2014 Oct;51(5):845-51
pubmed: 25037251
Horm Res Paediatr. 2017;87(6):377-384
pubmed: 28505610
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
JAMA. 2021 Jun 8;325(22):2262-2272
pubmed: 34077499
Diabetes Res Clin Pract. 2008 Oct;82(1):73-9
pubmed: 18701183
J Clin Endocrinol Metab. 2011 Jan;96(1):159-67
pubmed: 20962021
Diabetes Care. 2021 Mar;44(3):817-825
pubmed: 33436401
J Pediatr. 2009 Nov;155(5):668-72.e1-3
pubmed: 19643434
J Diabetes Sci Technol. 2019 Mar;13(2):271-275
pubmed: 30066574
Diabetes Care. 2022 Nov 1;45(11):2689-2697
pubmed: 36190810
Diabetes Care. 2005 Mar;28(3):626-31
pubmed: 15735199
Diabetes Technol Ther. 2019 Sep;21(9):493-498
pubmed: 31287721
Front Clin Diabetes Healthc. 2022 Sep 09;3:968113
pubmed: 36992756
N Engl J Med. 2021 Nov 18;385(21):2015
pubmed: 34788519
Diabetes Care. 2018 Dec;41(12):2648-2668
pubmed: 30425094
Diabetes Technol Ther. 2011 Nov;13(11):1091-9
pubmed: 21919735
Pediatr Diabetes. 2016 Jun;17(4):266-73
pubmed: 25951940
Diabetes Technol Ther. 2023 Jan;25(1):13-19
pubmed: 36223197
Curr Diab Rep. 2017 Sep;17(9):66
pubmed: 28726154
Diabetes Res Clin Pract. 2008 Jun;80(3):371-9
pubmed: 18304674
J Diabetes Sci Technol. 2019 Nov;13(6):1135-1141
pubmed: 30854886